This article is more than 5 years old. Information may no longer be current.
21st Century Oncology appoints national chief science officer
Click Here to Manage Email Alerts
21st Century Oncology, appointed Steven Finkelstein, MD, as the company’s national chief science officer.
“Dr. Finkelstein has demonstrated a continuous commitment to provide cancer patients with access to novel therapies in the local communities he serves,” Constantine Mantz, MD, 21st Century oncology’s chief medical officer, said in a press release. “We are proud he accepted the offer to become the company’s Chief Science Officer to expand access to local clinical trials to cancer patients nationwide.”
Finkelstein’s areas of interest include prostate cancer, sarcoma and use of radiation-driven, personalized systemic therapy. He holds several leadership roles with ASCO, the American Society for Therapeutic Radiology and Oncology, the Radiological Society of North America, and the Radiation Therapy Oncology Group.
“I look forward to advancing the company’s mission of increasing patient access to novel cancer care,” Finkelstein said. “I am proud to better serve cancer patients nationwide by providing access to clinical trials in local communities, close to patient’s homes.”